US-based biotechnology company Thermo Fisher Scientific has reached an agreement to acquire Patheon through a tender offer for $35 a share in cash.
The purchase consideration for the acquisition will amount to $7.2bn, including the assumption of $2bn of net debt owed by the target company.
The target company is a Netherlands-based contract development and manufacturing organisation.
Norgine has reached an agreement for the acquisition of Merus Labs International in a cash deal.
The entire issued and outstanding common shares of the target company will be acquired at a price of $1.65 a share, which represents an enterprise value of approximately $342m for Merus Labs.
The acquisition will be financed through existing cash and recently secured credit facilities.
Netherlands-based Norgine specialises in gastroenterology, hepatology, cancer and supportive care, while Canadian firm Merus Labs is a specialist pharmaceutical company focused on oncology, women's health, cardiovascular, urology, infectious diseases.